CTLA4 and thyroid gland carcinoma: Future directions for CTLA-4-and PD-1/PD-L1-based immunotherapy in thyroid carcinoma, including combination therapy and individualised treatment, and understanding the complex mechanisms of combined therapy will continue to be explored.